预约演示
更新于：2026-02-27
Tianeptine Sodium
噻奈普汀钠
更新于：2026-02-27
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 法国 (1987-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H25ClN2NaO4S |
InChIKeyUDFCCNYPCCUJOO-UHFFFAOYSA-N |
CAS号30123-17-2 |
关联
14
项与 噻奈普汀钠 相关的临床试验NCT05935059
Evaluation of the Efficacy of Perioperative Administration of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery. A Double-Blinded Randomized Controlled Trial.
NCT06012552
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19 With the Study of the Pathophysiology of the Phenomenon Using Positron Emission Tomography, Biochemical, Immunological and Electrophysiological Parameters.
NCT04446039
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data
100 项与 噻奈普汀钠 相关的临床结果
登录后查看更多信息
100 项与 噻奈普汀钠 相关的转化医学
登录后查看更多信息
100 项与 噻奈普汀钠 相关的专利（医药）
登录后查看更多信息
701
项与 噻奈普汀钠 相关的文献（医药）2026-03-01Biological psychiatry global open science
μ Opioid Modulation of Sensorimotor Functional Connectivity in Autism: Insights From a Pharmacological Neuroimaging Investigation Using Tianeptine
Article
作者: Lythgoe, David J ; Batalle, Dafnis ; Robertson, Dene M ; Blainey, Sarah ; Leaman, Sydney ; Valasakis, Ioannis ; Wong, Nichol M L ; Ivin, Glynis ; Holiga, Štefan ; McAlonan, Gráinne M ; Dimitrov, Mihail ; Tricklebank, Mark D ; Murphy, Declan G M ; França, Lucas G S ; Findon, James L ; Wichers, Robert H ; He, Jason ; Daly, Eileen ; Stoencheva, Vladimira
Background:
Reproducible patterns of atypical functional connectivity (FC) of sensorimotor and higher-order networks have previously been identified in the autistic brain. However, the neurosignaling pathways underpinning these differences remain unclear. The μ opioid system is involved in sensory processing as well as social and reward behaviors and has been implicated in autism, suggesting a potential role in shaping the autistic brain. Therefore, we tested the hypothesis that there is atypical involvement of the μ opioid system in these networks in autism.
Methods:
We used a placebo-controlled, double-blind, randomized, crossover study design to compare the effects of a single dose of the μ opioid receptor agonist tianeptine in autistic (n = 20) and nonautistic (n = 21) males on FC of sensorimotor and frontoparietal networks.
Results:
We found that tianeptine increased FC of a sensorimotor network previously characterized by atypically low FC in autism. The connectivity of the frontoparietal network was not significantly shifted.
Conclusions:
Our findings suggest that μ opioid neurosignaling may contribute to functional brain differences in the sensorimotor network in autism. Given that sensorimotor system alterations are thought to be central to autism and contribute to other core autistic features, as well as adaptability and mental health, further research is warranted to explore the translational potential of μ opioid modulation in autism.
2026-01-01OBSTETRICS AND GYNECOLOGY
Emerging Substances and Perinatal Health
Review
作者: Manriquez, Maria ; Jones, Cresta W ; Chavan, Niraj R
Perinatal substance exposure is evolving rapidly, often before data on exposure outcomes are available. New exposures to substances include adulterants found in established drug supplies such as fentanyl, xylazine, nitazenes, and medetomidine, and substances promoted as herbal or natural supplements such as kratom and tianeptine. In addition, there are prescription medications being used in new or unintended ways, such as ketamine. This narrative review details some of the most common substances currently emerging in the United States and discusses the potential effects on pregnancy outcomes. It also highlights the importance of comprehensive inquiry into substance exposure and discussion regarding minimizing the risks of exposure in the setting of limited perinatal data.
2025-12-01Brain and Behavior
Real‐World Effects of Home‐Based Transcranial Direct Current Stimulation in Depression: A Randomized Controlled Trial of 3‐Week Versus 6‐Week Protocols
Article
作者: Roh, Daeyoung ; Do, Gangho ; Jhung, Kyungun ; Lee, Kiwon ; Chang, Jhin Goo ; Park, Jin Young ; Park, Sunyoung ; Ryu, Jin Sun ; Park, Hye Yoon ; Kim, Woo Jung ; Park, Jaesub
ABSTRACT:
Background:
Despite growing interest in home‐based transcranial direct current stimulation (tDCS) as a scalable treatment for depression, real‐world evidence regarding its effectiveness, cognitive impact, and safety remains limited. Moreover, the optimal stimulation duration for home‐based tDCS has not been clearly established. This study aimed to compare the clinical effects of two home‐based tDCS protocols—one with 3 weeks of active stimulation followed by 3 weeks of sham stimulation (3WA) and another with 6 weeks of active stimulation (6WA)—in patients with major depressive disorder (MDD).
Methods:
In this randomized controlled trial, participants diagnosed with MDD were assigned to either the 3WA or 6WA group. Depressive symptoms were measured using the Beck Depression Inventory‐II (BDI) and the Montgomery–Åsberg Depression Rating Scale (MADRS). Cognitive function was assessed with the Digit Symbol Substitution Test (DSST). Adverse events were systematically monitored, and the relationship between psychotropic medication use and adverse event frequency was analyzed using logistic regression.
Results:
Both groups showed significant improvements in depressive symptoms and cognitive performance across four assessment points (baseline, Weeks 3, 6, and 12). Linear mixed‐effects models revealed a significant main effect of time for both BDI (
F
= 33.67,
p
< 0.001) and MADRS scores (
F
= 34.50,
p
< 0.001), with no significant group‐by‐time interaction, indicating comparable efficacy between protocols. Model‐derived mean changes from baseline to Week 12 were −7.53 (95% CI −9.85 to −5.21) for BDI and −6.61 (95% CI −8.73 to −4.49) for MADRS. DSST scores also improved significantly over time (
F
= 55.8,
p
< 0.001), with a mean increase of +6.62 points (95% CI +5.17 to +8.05), again showing no significant group difference. Regarding safety, non‐medicated participants reported fewer adverse events, whereas those taking tianeptine experienced significantly more side effects compared with other medication groups.
Conclusions:
Both 3‐week and 6‐week active tDCS protocols were associated with improvements in depressive symptoms and cognitive function over time in this naturalistic clinical context; however, as the study did not include a sham control, these changes should be interpreted as comparative rather than causal effects. The 3‐ and 6‐week protocols demonstrated similar therapeutic outcomes, suggesting that shorter courses may be sufficient. These findings support the real‐world applicability of at‐home tDCS and highlight the need to consider concurrent pharmacotherapy when evaluating tolerability and safety.
Trial Registration:
ClinicalTrials.gov identifier: NCT05539131
89
项与 噻奈普汀钠 相关的新闻（医药）
2026-01-30
100 项与 噻奈普汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 法国 | 1987-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 重度抑郁症 | 临床3期 | 芬兰 | 2013-07-18 | |
| 枫糖尿病 | 临床前 | 巴西 | 2022-08-30 | |
| 癫痫 | 临床前 | 印度 | 2013-06-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 38 | 構簾鬱網壓製範鑰顧願(餘襯顧網鬱鬱觸遞鹽醖) = 齋齋壓壓積築鏇糧鹹鹹 齋遞範選醖廠蓋憲構蓋 (簾糧製醖廠願窪壓窪鹹, 9.8) 更多 | - | 2026-01-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用